Palatin Technologies, Inc. (NYSE Amex: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Our primary product in development is bremelanotide for the treatment of female sexual dysfunction. In addition, we have development programs or drug candidates for erectile dysfunction, pulmonary diseases, heart failure, obesity and inflammatory diseases.